Afimkibart para la artritis reumatoide moderada a grave con intolerancia a los inhibidores de TNF/JAK

Afimkibart

Afimkibart

Placebo

Change from Baseline in Disease Activity Score-28 for Rheumatoid Arthritis with C-Reactive Protein (DAS28-CRP)

Change From Baseline in the ACR Core Set - High-sensitivity C-reactive Protein (hsCRP)

Change From Baseline in the ACR Core Set - Patient's Global Assessment of Arthritis Pain-Visual Analog Scale (PGA Arthritis Pain-VAS)

Change From Baseline in the ACR Core Set - Patient's Global Assessment of Disease Activity-Visual Analog Scale (PaGADA-VAS)

Change From Baseline in the ACR Core Set - Health Assessment Questionnaire- Disability Index (HAQ-DI)

Change from Baseline in ACR20, ACR50 and ACR70 Response Rate

Percentage of Participants Achieving an American College of Rheumatology 20 Percent (%), 50% or 70% Improvement (ACR20/ACR50/ACR70)

Change from Baseline Disease Activity Score-28 for Rheumatoid Arthritis with Erythrocyte Sedimentation Rate (DAS28-ESR) Score

Change From Baseline in the ACR Core Set - Swollen Joint Count (SJC)

Change From Baseline in the ACR Core Set - Tender Joint Count (TJC)

Change From Baseline in the ACR Core Set - Physician's Global Assessment of Disease Activity-Visual Analog Scale (PhGADA-VAS)

Change from Baseline in Simplified Disease Activity Index (SDAI) Score

Change from Baseline in Clinical Disease Activity Index (CDAI) Score

Change from Baseline in Short Form-36 Health Survey (SF-36) Score

Change from Baseline Disease Activity Score-28 for Rheumatoid Arthritis with C-Reactive Protein (DAS28-CRP) Score

Percentage of Participants With Adverse Events (AEs)

Serum Concentration of RO7790121 at Specified Timepoints

Percentage of Participants With Anti-Drug Antibodies